Hasil Pencarian - John Powderly

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors

    519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors oleh John Powderly, Jennifer O’Neil, Ekta Patel, Teleen Norman, Meghan Duncan, Martin Huber, Andrae Vandross

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation

    717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalat... oleh Andrew Haydon, John Powderly, Timothy Wyant, James Vasselli, Drew Rasco, Meredith McKean, Elizabeth Ahern, Sophia Frentzas, Andrew Weickhardt, Inbar Amit, Aron Knickerbocker, Yanay Ofran, Paul de Souza, Jenny Tang, Lori Richards

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

    373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tum... oleh Yan Wang, John Powderly, Marc Ernstoff, Anthony Shields, Ulka Vaishampayan, John Wrangle, Sarina Piha-Paul, Anthony Olszanski, Lei Sun, Bradley Carthon, Kelly Curtis, Ilda Bidollari, Yangchun Du, Emily Putiri, Heather Losey, Bruce Dezube

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    518 First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors

    518 First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors oleh Lixia Wang, John Powderly, Tanios Bekaii-Saab, Susanna Ulahannan, Ngan Nguyen, Deborah Doroshow, Yan Xing, Mark Whidden, Carl Millward, Jonathan Benjamin, S John Weroha, Frances Valdes-Albini, Kimberly Walter, Andrew Wrong, Paul Del Castillo, Steven Isakoff

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

    750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers oleh Lei Zheng, Jun Gong, John Powderly, Tanios Bekaii-Saab, Angela Alistar, Siqing Fu, Nashat Gabrail, Dae Won Kim, Yvonne Saenger, Olatunji Alese, Apollina Goel, Nataliya Uboha, Laura Agensky, Matteo Levisetti, Steven Margossian, Steve Quayle, J Eva Selfridge, Jorge Chaves, Jin Zhaohui

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

    710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advance... oleh John Powderly, Jae Lyun Lee, Jung-Yun Lee, Byoung Chul Cho, Kyoung-Ho Pyo, Soohyeon Lee, Dong Kim, Myoung Ho Jang, Byoung Yong Shim, Sang Joon Shin, Nari Yun, Mina Ham, Julia Cohen, Hyo Jin Lee, Kyoyoung Lee, Hyunjin Kang, Jea Hwan Kim, Mi hyun Kim

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1

    611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1 oleh David Miller, John Powderly, Suthee Rapisuwon, Sanjay Goel, Bartosz Chmielowski, Richard Wu, Meredith McKean, Damiano Fantini, Yousef Zakharia, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Ekta Patel, Anurag Gupta, George Lee, Meghan Duncan, Meredith Pelster, Randy Hurley, Aika Siu, David Crowe, Sattanathan Paramasivan, Katarina Luptakova

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) oleh John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: